Jaguar Animal Health Files 8K - Regulation FD >JAG
Post# of 22755
(Total Views: 534)
Posted On: 07/28/2017 9:29:49 AM
Jaguar Animal Health Files 8K - Regulation FD >JAGX
29 minutes ago - DJNF
Jaguar Animal Health Inc. (JAGX) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on July 28, 2017.
On July 28, 2017, the management team of Jaguar Animal Health, Inc. ("Jaguar"
hosted an investors' call to announce the approval by shareholders of Jaguar and Napo Pharmaceuticals, Inc. ("Napo" of the proposals recommended by the Jaguar and Napo boards regarding the previously announced merger between the two companies. On the call, Jaguar also provided updated guidance that Mytesi(R), a first-in-class anti-secretory agent indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, is forecasted to generate approximately $7 million in revenue by April 2018.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/158560...76_18k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/158560...-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
(END) Dow Jones Newswires
July 28, 2017 08:59 ET (12:59 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
29 minutes ago - DJNF
Jaguar Animal Health Inc. (JAGX) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on July 28, 2017.
On July 28, 2017, the management team of Jaguar Animal Health, Inc. ("Jaguar"
hosted an investors' call to announce the approval by shareholders of Jaguar and Napo Pharmaceuticals, Inc. ("Napo" of the proposals recommended by the Jaguar and Napo boards regarding the previously announced merger between the two companies. On the call, Jaguar also provided updated guidance that Mytesi(R), a first-in-class anti-secretory agent indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, is forecasted to generate approximately $7 million in revenue by April 2018. The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/158560...76_18k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/158560...-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
(END) Dow Jones Newswires
July 28, 2017 08:59 ET (12:59 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼